[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cannabis-abuse\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cannabis-abuse":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,69,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":54,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100619125","neuroimaging-of-adolescent-cannabis-use-treatment-100619125",false,"NCT07340554","Neuroimaging of Adolescent Cannabis Use Treatment","Neuroimaging of Instrumental Learning Networks in Adolescent Cannabis Use Treatment","ACT","Inclusion Criteria:\n\n* 14-17 year old youth\n* Guardian 18 years or older\n* Youth is MRI-eligible: No metal implants, prosthetics, orthodontic devices, transdermal medication patches, piercings and\u002For hair or eyelash extensions that cannot easily be removed, metallic ink tattoos on the neck or face, or claustrophobia, and are not pregnant\n* Youth must endorse having used cannabis at least once per week over the past month OR youth must have been diagnosed with cannabis use disorder within the past three months\n\nExclusion Criteria:\n\n* Youth has a history of Fetal Alcohol Spectrum Disorder, intellectual disorders, pervasive development disorder or autism spectrum disorder, psychotic disorders, history of neurological problems (epilepsy, traumatic brain injury, brain tumor, cerebrovascular disease) by parent\u002Fguardian report\n* Youth or caretaker who is monolingual non-English speaker\n* Youth who is currently experiencing active psychosis symptoms or suicidal\u002Fhomicidal ideation or who has been hospitalized within the past 6 months for psychosis or suicidality\u002Fhomicidality\n* Youth who is currently undergoing contingency management treatment for cannabis use disorder","ALL","14 Years","17 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is testing whether brain activity related to learning can help predict how well teens respond to a treatment program designed to reduce cannabis use. Teens ages 14-17 will complete a brain scan and then take part in 10 weekly virtual sessions where they report cannabis use and complete drug tests at home. Participants can earn prizes for staying cannabis-free.",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Cannabis Use","Cannabis Dependence","Cannabis Use Disorder","Cannabis Abuse","Cannabis Intoxication","Cannabis Smoking","Cannabis Withdrawal","Cannabis-Related Disorder","Cannabis Abuse, in Remission","Cannabis Abuse, Episodic Use","Marijuana","Marijuana Abuse","Marijuana Use","Marijuana Smoking","Marijuana Dependence","Marijuana User","Marijuana-Related Disorder","Marijuana Use Disorder","Addiction","Addiction, Substance","Substance Use","Substance Use Disorders","Substance Dependence","Substance Abuse","Substance Related Problem","Substance Abuse Drug Chronic",[55,38,46],"Cannabis","RECRUITING","2026-06-18",{"date":59,"type":60},"2026-06-22","ACTUAL",{"date":62,"type":60},"2026-06-15",{"date":64,"type":22},"2030-05-01",{"name":66,"class":67},"Indiana University","OTHER",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":68},"100633203","phase-2-effect-of-semaglutide-on-cannabis-use-in-adults-with-cannabis-use-disorder-100633203","NCT07523633","Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder","A Randomized, Double-Blind, Placebo-Controlled Trial of Semaglutide for Reducing Cannabis Use in Adults With Cannabis Use Disorder","HASHTAG","Inclusion Criteria:\n\n1. Informed oral and written consent.\n2. Meets the criteria for cannabis use disorder (CUD) according to DSM-5 or ICD-10.\n3. Currently seeking to cut down or stop cannabis use.\n4. Positive urine test for cannabinoids.\n5. Body mass index (BMI) ≥ 23 kg\u002Fm².\n6. Age 18-70 years.\n7. Recent frequent cannabis use, defined as use on ≥16 days out of the past 28 days.\n8. Cannabis use (smoked, vaped, edibles) equivalent to THC doses of ≥14 grams in the past 28 days before baseline.\n9. Ability to comply with study procedures and follow-up.\n\nExclusion Criteria:\n\n1. Currently meeting non-cannabis\u002Ftobacco substance use disorder (ICD-10 or DSM-5).\n2. Current or past diagnosis of severe psychiatric illness, defined as schizophrenia, bipolar disorder, or other psychoses, within the past five years.\n3. Suicide attempt or suicidal behavior within the past five years.\n4. Severe neurological disorders, including previous severe traumatic brain injury, stroke, or intracranial hemorrhage.\n5. Type 1 diabetes and type 2 diabetes.\n6. Pregnant or potentially pregnant women: Women of childbearing potential (WOCBP) who are pregnant, breastfeeding, planning to become pregnant within the next eight months (including 20 weeks of treatment plus two months after discontinuation of semaglutide), or not using effective contraception throughout the study period. Effective methods include combined hormonal contraception (oral, intravaginal, transdermal), progestogen-only hormonal contraception (oral, implant, injection), intrauterine device\u002Fsystem (IUD\u002FIUS), bilateral tubal occlusion, partner with vasectomy, or sexual abstinence. WOCBP with a measured serum human chorionic gonadotropin (hCG) level \\>3 U\u002FL at inclusion will also be excluded.\n7. Impaired liver function (liver transaminases \\>3 times the upper reference limit)\n8. Impaired renal function (eGFR \\\u003C50 ml\u002Fmin and\u002For plasma creatinine \\>150 µmol\u002FL).\n9. Impaired pancreatic function (past or current acute or chronic pancreatitis and\u002For amylase \\>2 times the upper limit).\n10. History of medullary thyroid carcinoma (MTC) and\u002For family history of MTC and\u002For Multiple Endocrine Neoplasia type 2 (MEN 2).\n11. Heart disease is defined as decompensated heart failure (NYHA class III or IV), unstable angina pectoris, and\u002For myocardial infarction within the past 12 months.\n12. Uncontrolled hypertension (systolic blood pressure \\>180 mmHg, diastolic blood pressure \\>110 mmHg).\n13. Receipt of experimental medication within the past 30 days.\n14. Use of weight-loss medication within the past 3 months.\n15. Hypersensitivity to the active substance or any of the excipients.\n16. For patients undergoing brain scanning only:\n\n    Contraindications to MRI scanning (magnetic implants, pacemaker, claustrophobia, etc.).\n17. Inability to speak and\u002For understand Danish.\n18. Other conditions: Any other condition that, in the investigator's opinion, may interfere with participation in the trial.","18 Years","70 Years",{"count":80,"type":22},100,[82],"PHASE2","The HASHTAG Study is investigating whether the medicine semaglutide can help adults with cannabis use disorder (CUD) reduce their cannabis use. Participants will be randomly assigned to receive either semaglutide or a placebo. The first 50 participants will have functional brain scans (fMRI) to investigate how the brain responds to cannabis-related cues. The main outcome after 20 weeks is whether semaglutide reduces cannabis use compared to placebo. Changes in brain activity in response to cannabis cues will be explored as a secondary outcome.",[30,85,31,29,86],"Cannabis Use Disorders","Cannabis Addiction",[88,89,90,91,92,93,94,95,96,97,98,99,100,101],"GLP-1","Glucagon-like peptide 1","semaglutide","fMRI","cannabis","GLP-1 receptor agonist","Randomized Controlled Trial","Double-Blind Method","Placebo-Controlled","Neuroimaging","Brain activity","Cue reactivity","Craving","Drug therapy","2026-05-12",{"date":104,"type":60},"2026-05-14",{"date":106,"type":60},"2026-04-30",{"date":108,"type":22},"2028-04-30",{"name":110,"class":67},"Anders Fink-Jensen, MD, DMSci",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":68},"100599961","exercise-intervention-as-treatment-for-people-using-cannabis-exit-c-100599961","NCT07091292","Exercise Intervention as Treatment for People Using Cannabis (ExIT-C)","Exercise Intervention as Treatment for People Using Cannabis (ExIT-C)-a Randomized Controlled Trial to Investigate the Effectiveness of Aerobic Exercise on Cannabis Dependence and Use Disorder","ExIT-C","Inclusion Criteria:\n\n* Young adults of 18-40 years old\n* Able to read and communicate in English and\u002For Chinese\n* Able to give informed consent\n* Using cannabis or marijuana as the primary psychoactive substance of abuse\n* Suffering from cannabis addiction, defined by:\n\n  i. Cannabis Dependence with an SDS score ≥ 3, or ii. Cannabis Use Disorder according to the Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5), or iii. Cannabis Harmful Use or Dependence according to the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) or Clinical descriptions and diagnostic requirements for International Classification of Diseases 11th Revision (ICD-11) mental, behavioral, and neurodevelopmental disorders.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 or \\> 40 years old\n* Unable to read English or Chinese\n* Unable to give informed consent\n* Absolute and\u002For relative contraindications to exercise training as indicated by the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+) and the electronic Physical Activity Readiness Medical Examination (ePARmed-X+)\n* Had been diagnosed with the following disorders, including:\n\n  i. Neurodevelopmental Disorders DSM-5: Intellectual Disabilities, Communication Disorders, Specific Learning Disorder, Autism Spectrum Disorder and Motor Disorders ICD-11: Disorders of intellectual development (6A00), Developmental speech or language disorders (6A01), Autism spectrum disorder (6A02), Developmental learning disorder (6A03), Developmental motor coordination disorder (6A04), Stereotyped movement disorder (6A06), Primary tics or tic disorders (8A05.0) ii. Other DSM-5 defined Substance Use Disorder greater than mild in severity (i.e., severity score ≥ 2), except for tobacco or caffeine iii. Neurocognitive Disorders (DSM-5, or ICD-11 6D70-72 \\& 6D80-86)","40 Years",{"count":121,"type":22},60,[25],"In Hong Kong, although the total number of drug abusers is trending down in recent years, the number of cannabis users continues to surge. The misuse of cannabis, if left unattended, predisposes various degrees of dependence and use disorders, which could later on induce psychotic disorders and schizophrenia. Effective strategies combating cannabis dependence and cannabis use disorder (CUD) are therefore warranted.\n\nExercise presents as a low-cost and low-stigma alternative to traditional pharmacotherapy and psychotherapy in the treatment of substance use disorders, which also promotes physical well-being with virtually no side effects. While exercise has some success in treating use disorders of stimulants, alcohol, and tobacco, evidence of its effects on CUD remains scarce. Hence, the present study will be conducted to assess the effectiveness of a 12-week aerobic exercise training regimen on reducing cannabis dependence and the severity of CUD.\n\nParticipants with cannabis dependence will be randomly assigned to either the exercise or the control group. Participants assigned to the exercise group will partake in a 12-week aerobic exercise training program of vigorous-intensity using indoor bikes, whereas those assigned to the control group will perform sham exercise of very light-intensity on indoor bikes. The 12-week study is divided into three (3) 4-week phases:\n\n1. Intensive Intervention - all participants will exercise twice a week under supervision.\n2. Active Intervention - all participants will exercise once a week under supervision.\n3. Passive Maintenance - no supervised exercise sessions will be provided. All participants will receive exercise reminders via weekly text messages.\n\nCannabis use-related, cognitive, and physical outcomes will be assessed every 4 weeks, whereas withdrawal symptoms will be assessed and urine quick test administered every week.",[31,29,30],[126,92,127,128,129],"exercise","cannabis use disorder","cannabis dependence","substance abuse","2025-07-21",{"date":132,"type":60},"2025-07-29",{"date":134,"type":60},"2025-07-02",{"date":136,"type":22},"2028-12",{"name":138,"class":67},"The University of Hong Kong"]